The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sayfitdinkhuzhaev Z.F.

Siberian State Medical University

Zhukova N.G.

Siberian State Medical University

Nasyrova R.F.

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology

Gaponova O.V.

Siberian State Medical University

Zhukova I.A.

Siberian State Medical University

Masenko A.Ya.

Siberian State Medical University

Baydanova A.N.

Siberian State Medical University

Pathophysiological and neurobiological basis for the development of depression in patients with Parkinson’s disease

Authors:

Sayfitdinkhuzhaev Z.F., Zhukova N.G., Nasyrova R.F., Gaponova O.V., Zhukova I.A., Masenko A.Ya., Baydanova A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(1): 7‑12

DOI: 10.17116/jnevro20261260117

Read: 689 times

Buy for 300₽
Contact the author
Table of contents

PATHOPHYSIOLOGICAL AND NEUROBIOLOGICAL BASIS FOR THE DEVELOPMENT OF DEPRESSION IN PATIENTS WITH PARKINSON’S DISEASE
PATHOPHYSIOLOGICAL AND NEUROBIOLOGICAL BASIS FOR THE DEVELOPMENT OF DEPRESSION IN PATIENTS WITH PARKINSON’S DISEASE

To cite this article:

Sayfitdinkhuzhaev ZF, Zhukova NG, Nasyrova RF, Gaponova OV, Zhukova IA, Masenko AYa, Baydanova AN. Pathophysiological and neurobiological basis for the development of depression in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2026;126(1):7‑12. (In Russ.)
https://doi.org/10.17116/jnevro20261260117

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Factors of depression acco­rding to acti­graphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55
Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107
Inve­stigation of the rela­tionship of indi­vidual characteristics of the brain bioelectrical acti­vity with levels of mental stress, aggression, anxiety, and depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):108-117
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Gender characteristics of cardiovascular diseases psychosocial risk factors asso­ciations with sleep quality in an open urban popu­lation. Russian Journal of Preventive Medi­cine. 2025;(6):67-73
Dysfunctional pelvic pain in women. Russian Journal of Pain. 2025;(2):32-37
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Abstract:

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases, second only to Alzheimer’s disease. PD is characterized by multisystemic lesions and steady progression of the pathological process, which inevitably leads to the occurrence of various symptoms. PD symptoms are divided into motor and non-motor. It is generally accepted that non-motor symptoms precede motor ones and appear several decades before motor symptoms. The most common non-motor symptom of PD is depression, which significantly reduces patients’ quality of life. The review addresses recent studies of the pathophysiology of depression in PD patients. The analysis showed the involvement of the substantia nigra, the raphe nuclei, and the locus ceruleus in the development of depression in PD patients. The molecular basis of their dysfunction is a deficiency of dopamine, serotonin, and norepinephrine. A detailed study of the neurobiological mechanisms of the development and progression of depression will create highly effective and pathogenetically based therapeutic areas.

Keywords:

Parkinson’s disease
depression
pathophysiology
dopamine deficiency
neurobiological pattern
neurodegeneration

Authors:

Sayfitdinkhuzhaev Z.F.

Siberian State Medical University

Zhukova N.G.

Siberian State Medical University

Nasyrova R.F.

V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology

Gaponova O.V.

Siberian State Medical University

Zhukova I.A.

Siberian State Medical University

Masenko A.Ya.

Siberian State Medical University

Baydanova A.N.

Siberian State Medical University

Received:

18.03.2025

Accepted:

21.03.2025

Close metadata

References:

  1. Goiran T, Eldeeb MA, Zorca CE, et al. Hallmarks and Molecular Tools for the Study of Mitophagy in Parkinson’s Disease. Cells. 2022;11(13):2097. https://doi.org/10.3390/cells11132097
  2. Sal’kov VN, Khudoerkov RM, Voronkov DN, et al. Morphochemical changes in the substantia nigra cellular structures in Parkinson’s disease. Arhiv patologii. 2017;79(5):3-9. (In Russ.). https://doi.org/10.17116/patol20177953-9
  3. Sayfitdinkhuzhaev ZF, Zhukova NG, Baidanova AN. Neuroinflammation as an Integral Component of Neurodegeneration in Parkinson’s Disease. Personalized Psychiatry and Neurology. 2024;4(4):26-33.  https://doi.org/10.52667/2712-9179-2024-4-4-26-33
  4. Park JS, Davis RL, Sue CM. Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives. Curr Neurol Neurosci Rep. 2018;18(5):21.  https://doi.org/10.1007/s11910-018-0829-3
  5. Zhu M, Liu X, Ye Y, et al. Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease. Front Immunol. 2022;13:937555. https://doi.org/10.3389/fimmu.2022.937555
  6. Üremiş N, Üremiş MM. Oxidative/Nitrosative Stress, Apoptosis, and Redox Signaling: Key Players in Neurodegenerative Diseases. J Biochem Mol Toxicol. 2025;39(1):e70133. https://doi.org/10.1002/jbt.70133
  7. Mironova YuS, Zhukova IA, Zhukova NG, et al. Parkinson’s disease and glutamate excitotoxicity. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6-2):50-54. (In Russ.). https://doi.org/10.17116/jnevro201811806250
  8. Tavadian ZD, Bakunts GO. Nonmotor signs of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(5):81-85. (In Russ.).
  9. Zhukova IA, Zhukova NG, Alifirova VM. No-motor impairment in patients with Parkinson’s disease. Byulleten’ sibirskoy meditsiny. 2009;8(1(2)):136-141. (In Russ.). https://doi.org/10.20538/1682-0363-2009-1(2)-136-141
  10. Zhukova NG, Matveeva MV, Kazantseva PE, et al. Sarcopenia as a non-motor symptom of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(9):15-22. (In Russ.). https://doi.org/10.17116/jnevro202412409115
  11. Pereira ES, Rocha RS, Espinoso SQ, et al. Área foliar atacada pelo bicho-mineiro de uma lavourade de café arábica, cultivar obatã 603. Revista Univap. 2022;(40):325.  https://doi.org/10.18066/revistaunivap.v22i40.809
  12. Wang S, Mao S, Xiang D, et al. Association between depression and the subsequent risk of Parkinson’s disease: A meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018;30(86):186-192.  https://doi.org/10.1016/j.pnpbp.2018.05.025
  13. Milyukhina IV. Pathogenesis, clinical features, and treatments of depression in Parkinson’s disease. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2019;11(2):93-99. (In Russ.). https://doi.org/10.14412/2074-2711-2019-2-93-99
  14. Zakharov DV, Kokareva DD. Comorbidity of sialorrhea and depression in patients with Parkinson’s disease, their mutual influence on the severity of symptoms and the success of therapy. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2024;16(6):105-111. (In Russ.). https://doi.org/10.14412/2074-2711-2024-6-105-111
  15. Nagy A, Schrag A. Neuropsychiatric aspects of Parkinson’s disease. J Neural Transm. 2019;(126):889-896.  https://doi.org/10.1007/s00702-019-02019-7
  16. Ahmad MH, Rizvi MA, Ali M, et al. Neurobiology of depression in Parkinson’s disease: Insights into epidemiology, molecular mechanisms and treatment strategies. Ageing Res Rev. 2023;(85):101840. https://doi.org/10.1016/j.arr.2022.101840
  17. Akhmadeeva GN, Magzhanov RV, Tayupova GN, et al. Anxiety and depressive disorders in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(1-2):54-58. (In Russ.). https://doi.org/10.17116/jnevro20171171254-58
  18. Ray S, Agarwal P. Depression and Anxiety in Parkinson Disease. Clin Geriatr Med. 2020;36(1):93-104.  https://doi.org/10.1016/j.cger.2019.09.012
  19. Cong S, Xiang C, Zhang S, et al. Prevalence and clinical aspects of depression in Parkinson’s disease: A systematic review and meta-analysis of 129 studies. Neurosci Biobehav Rev. 2022;141:104749. https://doi.org/10.1016/j.neubiorev.2022.104749
  20. Senkevich KA, Milyukhina IV, Beletskaya MV, et al. Clinical features of Parkinson’s disease in patients with mutations and polymorphic variants of the GBA gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10): 81-86. (In Russ.). https://doi.org/10.17116/jnevro201711710181-86
  21. Hemmerle AM, Herman JP, Seroogy KB. Stress, depression and Parkinson’s disease. Exp Neurol. 2012;233(1):79-86.  https://doi.org/10.1016/j.expneurol.2011.09.035
  22. Jellinger KA. The pathobiological basis of depression in Parkinson disease: challenges and outlooks. J Neural Transm. 2022;(129):1397-1418. https://doi.org/10.1007/s00702-022-02559-5
  23. Schapira A, Chaudhuri K, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18:435-450.  https://doi.org/10.1038/nrn.2017.62
  24. Dallé E, Mabandla MV. Early Life Stress, Depression and Parkinson’s Disease: A New Approach. Mol Brain. 2018;11(1):18.  https://doi.org/10.1186/s13041-018-0356-9
  25. Menon B, Nayar R, Kumar S, et al. Parkinson’s Disease, Depression, and Quality-of-Life. Indian Journal of Psychological Medicine. 2015;37(2):144-148.  https://doi.org/10.4103/0253-7176.155611
  26. Mueller C, Rajkumar AP, Wan YM, et al. Assessment and Management of Neuropsychiatric Symptoms in Parkinson’s Disease. CNS Drugs. 2018;(32):621-635.  https://doi.org/10.1007/s40263-018-0540-6
  27. Galts CP, Bettio LE, Jewett DC, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci Biobehav Rev. 2019;102:56-84.  https://doi.org/10.1016/j.neubiorev.2019.04.002
  28. Even C, Weintraub D. Is depression in Parkinson’s disease (PD) a specific entity? J Affect Disord. 2012;139(2):103-112.  https://doi.org/10.1016/j.jad.2011.07.002
  29. Weintraub D, Mamikonyan E. The Neuropsychiatry of Parkinson Disease: A Perfect Storm. Am J Geriatr Psychiatry. 2019;27(9):998-1018. https://doi.org/10.1016/j.jagp.2019.03.002
  30. Toomsoo T, Randver R, Liepelt-Scarfone I, et al. Prevalence of depressive symptoms and their association with brainstem raphe echogenicity in patients with Parkinson’s disease and non-PD controls. Psychiatry Res Neuroimaging. 2017;268:45-49.  https://doi.org/10.1016/j.pscychresns.2017.08.005
  31. Sgambato-Faure V, Tremblay L. Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states. J Neural Transm. 2018;(125): 485-500.  https://doi.org/10.1007/s00702-017-1693-z
  32. Kendler KS. The Phenomenology of Major Depression and the Representativeness and Nature of DSM Criteria. Am J Psychiatry. 2016;173(8):771-780.  https://doi.org/10.1176/appi.ajp.2016.15121509
  33. Jellinger KA. The pathobiological basis of depression in Parkinson disease: challenges and outlooks. J Neural Transm (Vienna). 2022;129(12):1397-1418. https://doi.org/10.1007/s00702-022-02559-5
  34. Yadav D, Kumar P. Restoration and targeting of aberrant neurotransmitters in Parkinson’s disease therapeutics. Neurochem Int. 2022;156:105327. https://doi.org/10.1016/j.neuint.2022.105327
  35. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573-580.  https://doi.org/10.1016/S1474-4422(10)70106-X
  36. Muñoz A, Lopez-Lopez A, Labandeira CM, et al. Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA. Front Neuroanat. 2020;14:26.  https://doi.org/10.3389/fnana.2020.00026
  37. Leal PC, Bispo JM, Lins LC, et al. Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism. Brain Res Bull. 2019;146:213-223.  https://doi.org/10.1016/j.brainresbull.2019.01.009
  38. Ilkiw JL, Kmita LC, Targa AD, et al. Dopaminergic Lesion in the Olfactory Bulb Restores Olfaction and Induces Depressive-Like Behaviors in a 6-OHDA Model of Parkinson’s Disease. Mol Neurobiol. 2019;56(2):1082-1095. https://doi.org/10.1007/s12035-018-1134-5
  39. Vriend C, Pattij T, van der Werf YD, et al. Depression and impulse control disorders in Parkinson’s disease: two sides of the same coin?. Neurosci Biobehav Rev. 2014;38:60-71.  https://doi.org/10.1016/j.neubiorev.2013.11.001
  40. Speranza L, di Porzio U, Viggiano D, et al. Dopamine: The Neuromodulator of Long-Term Synaptic Plasticity, Reward and Movement Control. Cells. 2021;10(4):735.  https://doi.org/10.3390/cells10040735
  41. Wang JY, Fan QY, He JH, et al. SLC6A4 Repeat and Single-Nucleotide Polymorphisms Are Associated With Depression and Rest Tremor in Parkinson’s Disease: An Exploratory Study. Front Neurol. 2019;10:333.  https://doi.org/10.3389/fneur.2019.00333
  42. Maillet A, Krack P, Lhommée E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain. 2016;139(Pt 9):2486-2502. https://doi.org/10.1093/brain/aww162
  43. Peters KZ, Cheer JF, Tonini R. Modulating the Neuromodulators: Dopamine, Serotonin, and the Endocannabinoid System. Trends Neurosci. 2021;44(6):464-477.  https://doi.org/10.1016/j.tins.2021.02.001
  44. Lagière M, Bosc M, Whitestone S, et al. A Subset of Purposeless Oral Movements Triggered by Dopaminergic Agonists Is Modulated by 5-HT2C Receptors in Rats: Implication of the Subthalamic Nucleus. Int J Mol Sci. 2020;21(22):8509. https://doi.org/10.3390/ijms21228509
  45. Liu Y, Zhao J, Fan X, et al. Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders. Front Psychiatry. 2019;10:286.  https://doi.org/10.3389/fpsyt.2019.00286
  46. Ehgoetz Martens KA, Lewis SJ. Pathology of behavior in PD: What is known and what is not? J Neurol Sci. 2017;374:9-16.  https://doi.org/10.1016/j.jns.2016.12.062
  47. Nagy A, Schrag A. Neuropsychiatric aspects of Parkinson’s disease. J Neural Transm (Vienna). 2019;126(7):889-896.  https://doi.org/10.1007/s00702-019-02019-7
  48. Zhou Z, Liu X, Chen S, et al. A VTA GABAergic Neural Circuit Mediates Visually Evoked Innate Defensive Responses. Neuron. 2019;103(3):473-488.e6.  https://doi.org/10.1016/j.neuron.2019.05.027
  49. Paredes-Rodriguez E, Vegas-Suarez S, Morera-Herreras T, et al. The Noradrenergic System in Parkinson’s Disease. Front Pharmacol. 2020;11:435.  https://doi.org/10.3389/fphar.2020.00435
  50. Gaval-Cruz M, Goertz RB, Puttick DJ, et al. Chronic loss of noradrenergic tone produces β-arrestin2-mediated cocaine hypersensitivity and alters cellular D2 responses in the nucleus accumbens. Addict Biol. 2016;21(1):35-48.  https://doi.org/10.1111/adb.12174
  51. Madelung CF, Meder D, Fuglsang SA, et al. Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson’s Disease. Mov Disord. 2022;37(3):479-489.  https://doi.org/10.1002/mds.28945
  52. Doppler CEJ, Kinnerup MB, Brune C, et al. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson’s disease. Brain. 2021;144(9):2732-2744. https://doi.org/10.1093/brain/awab236
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.